| |
|
|
|
|
|
|
|||
|
Blood, Vol. 94 No. 8 (October 15), 1999:
pp. 2809-2818
By
From the Department of Clinical Chemistry, Microbiology and
Immunology, University of Ghent, University Hospital of Ghent, Ghent,
Belgium; and the Flanders Interuniversity Institute for Biotechnology
(VIB), Belgium.
Human immunodeficiency virus (HIV)-infected individuals develop an
acquired immune deficiency syndrome (AIDS) due to loss in their
lymphocyte numbers and cellular defects in T cells and antigen-presenting cells (APC). HIV infection of the thymus results in
deficient replenishment of the peripheral naive T-cell pool. The HIV
nef gene was shown to be important for progression towards AIDS
and cellular depletion of the infected thymus. Here, we demonstrate by
retroviral gene transfer that nef expression, in the absence of
other HIV genes, impaired human thymic T-cell development. Thymocytes
were generated in reduced numbers and downmodulated CD4 and CD8
INDIVIDUALS INFECTED WITH human
immunodeficiency virus (HIV) develop an acquired immune deficiency
syndrome (AIDS) due to progressive loss of CD4+ T cells,
T-helper cell function, and impaired or abnormal antigen-presenting cell (APC) function (reviewed by Levy1). In some long-term nonprogressors, HIV virus containing deletions in the nef gene has been isolated.2-4 Monkeys infected with nef
defective simian immunodeficiency virus (SIV) showed a decreased viral
load, did not develop AIDS,5 and mounted a protective
immune response against infection with wild-type SIV.6
These observations showed that the HIV nef gene
facilitates4 or may even be essential for AIDS
development.7,8 In the cytoplasma of infected cells, Nef is
a phosphorylated and N-myristoylated membrane-associated protein of 27 kD (HIV-1) or 34 kD (HIV-2 and SIV).8 In T-cell lines, it
was shown to downregulate cell surface CD4 and major histocompatibility
complex (MHC) class I expression by increased endocytosis.9,10 Depending on the study, T-cell receptor
(TCR) for antigen-mediated cellular responses were found to be either inhibited or enhanced (reviewed by Harris7).
The inability to replenish the naive T-cell pool in AIDS patients is
due to infection of the thymus. Upon highly active antiretroviral therapy, thymus-derived peripheral naive CD4+ T-cell count
increases in HIV-infected subjects.11 HIV infection disturbs human T-cell development as seen in seropositive
children12 or in the human thymus of severe combined
immunodeficiency (SCID)-hu mice infected with HIV.13,14 In
this latter model, nef was shown to be required for efficient
in vivo viral replication and depletion of thymocytes.15-17
However, as nef is known to enhance viral
infectivity,7,8 these observations cannot discriminate between virus-mediated or direct cellular effects of Nef in infected thymocytes. Transgenic (Tg) mice expressing nef in thymocytes and T cells have reduced CD4+ thymocyte and T-cell numbers
and show altered T-cell activation responses.18-20
Moreover, in mice Tg for the HIV genome, expressed in CD4+
APC, like macrophages and dendritic cells (DCs) and in CD4+
thymocytes and T cells, the observed AIDS-like pathology was due to
nef expression.21,22 Observations in Tg mice raised the possibility that nef function, independent of the presence of infectious virus or even other HIV genes, is responsible for human
thymocyte depletion and possibly even progression towards AIDS.
However, Nef function has never been addressed in human T-cell and DC
generation and function.
In this report, we demonstrate that T-cell precursors, expressing HIV-1
nef after retroviral gene transfer, were impaired in generating
T cells. Transduced thymocytes downmodulated CD4 and CD8 Our results indicate that HIV nef expression is responsible for
part of the thymic disturbances seen in HIV infection and may
contribute to AIDS development by reduced T-cell generation and T-cell
hyperresponsiveness. Aberrant mature DC function in HIV infection is
unlikely to result from nef expression in DCs.
Monoclonal Antibodies, Flow Cytometry, and Cell Sorting
Cell Culture and Purification of Progenitor Cells
Retroviral Gene Transfer The marker gene Enhanced Green Fluorescent Protein (EGFP) was placed 3' of an internal ribosome entry site (IRES) sequence in the LZRS retroviral vector.25 In this Nef control
vector (Fig 1A), an EcoRI-BamHI fragment containing the complete HIV-1
NL4-3 nef gene26 amplified by polymerase chain reaction (PCR) (Platinum Taq, Life Technologies, Paisley, Scotland) from the pNL4-3 plasmid (AIDS Research and Reference Reagent Program) was inserted 5' of the IRES sequence (Fig 1B) to generate the Nef+ vector. Direct sequencing (ABI, Perkin Elmer, Foster
City, CA) confirmed that the clone used contained the
published26 NL4-3 nef gene sequence. Retroviral
supernatants were prepared as described previously.24 The
Nef and Nef+ batches used in this report
contained approximately 2.5 × 105 and 6 × 105 transducing units/mL, respectively, titrated on Jurkat
cells. For generation of T cells, progenitor cells were transduced
once, 1 day (CD34+ CB cells, cultured in medium
supplemented with stem cell factor [SCF, 100 ng/mL], ftl3/flk-2
ligand [FL, 100 ng/mL], thrombopoietin (20 ng/mL]) or 2 days
(ISP4+ or CD34+ thymocytes,
cultured25 in medium supplemented with SCF [10 ng/mL] and
IL-7 [10 ng/mL]) after initiation of the culture (all cytokines from
R&D Systems Europe, Abingdon, UK). For generation of DCs, sorted
CD34+ CB cells were transduced once 2 days after initiation
of the culture as described below. For transduction, cells were seeded on RetroNectin (Takara Biomedicals, Otsu Shiga, Japan) coated culture
plates with half of the medium volume replaced by retroviral supernatants, supplemented with cytokines to keep final cytokine concentrations constant. After 3 days of culture, cells were harvested to determine transduction efficiency and used in subsequent assays.
Immunoblotting Cell lysates were run on 4% to 12% Bis-Tris polyacrilamide gels (Nupage, Novex, San Diego, CA) in 2-(N-morpholino) ethane sulfonic acid buffer in reducing conditions and proteins were blotted on polyvinylidene fluoride membranes (Novex). Blots were stained with the HIV-1 Nef monoclonal antibody EH-1 (AIDS Research and Reference Reagent Program) and antimouse IgG alkaline phosphatase conjugate (Sigma, Steinheim, Germany).Generation of Cell Lineages and Functional Assays Thymocytes. About 30,000 ISP4+ or 10,000 CD34+ thymus or CB cells were used in 7 to 30 day FTOC as described previously24 to study in vitro thymic repopulation. To study in vivo thymic repopulation, about 50,000 ISP4+ or 20,000 CD34+ CB cells were injected in the human thymus of SCID-hu mice that were irradiated (0.2 Gy, 0.04 Gy/minute) the day before. SCID-hu mice were obtained by transplantation of human fetal liver and thymus about 5 months before as described previously.23 Inherent to this model, the magnitude of engraftment of the thymus, as measured by the number of donor-derived thymocytes recovered several weeks after injection of progenitor cells, is highly variable27 (and our own unpublished observations). Therefore, calculation of precursor expansion is not possible. Human fetal tissue was obtained following the guidelines of the Medical Ethical Commission of the University Hospital of Ghent. Animals were treated according to the guidelines of the Laboratory Animal Ethical Commission of the University Hospital of Ghent. After 3 weeks (thymi injected with ISP4+ cells) or after 4 to 7 weeks (thymi injected with CD34+ CB cells), mice were killed and thymocytes were phenotyped and in some experiments sorted for EGFP, CD3, and CD27 expression. Sorted thymocytes from thymi injected with CD34+ CB cells were stimulated with phorbol myristate acetate (PMA; 2 ng/mL, Sigma) + phytohemagglutinin (PHA; 2 µg/mL, Murex, Dartford, United Kingdom) as described previously23 to induce cytokine expression. To induce proliferation, thymocytes were stimulated with PHA + IL-2 (Boehringer Mannheim) as described previously23 or with anti-CD3 antibody (OKT3, American Type Culture Collection) + PMA as described below. T cells.
SCID-hu thymocytes from thymi injected with transduced
ISP4+ or CD34+ CB cells were sorted as
described above and seeded on freshly isolated and irradiated (2.5 Gy)
allogeneic peripheral blood mononuclear cells (PBMCs) in medium
supplemented with PHA + IL-2 as described previously.23
After 14 days of culture, cells were harvested, phenotyped, and used to
induce cytokine expression (7 hours of culture, assay by reverse
transcription [RT]-PCR) or proliferation (36 hours of culture, assay
by DC.
Sorted CD34+ CB cells were cultured28 for 5 days (transduction 2 days after initiation of the culture) in complete
IMDM supplemented with SCF (100 ng/mL), FL (100 ng/mL), granulocyte
macrophage colony-stimulating factor (GM-CSF, 5 ng/mL), and tumor
necrosis factor
Retroviral-Mediated Transfer of nef To investigate the effect of nef gene expression on the development and function of human T cells and DCs, we constructed retroviral vectors containing the marker gene EGFP, without (Nef , Fig 1A) or with
(Nef+, Fig 1B) the HIV NL4-3 nef
gene.26 Due to the IRES,25 Nef+
transduced cells expressed both Nef and EGFP proteins from 1 bicistronic messenger RNA (mRNA). As expected, semiquantitative RT-PCR
on sorted Nef+ transduced cells showed a linear correlation
between the amount of mRNA for Nef and EGFP fluorescence intensity
(data not shown). Nef+ transduced cells expressed a
+/ 27 kD Nef protein as shown by immunoblotting (Fig 1C). We
transduced established T-cell lines to demonstrate the biological
activity of the Nef protein. Sup-T1 cells29 still expressed
CD4 and MHC class I after transduction with Nef
retroviral supernatant at the same level as nontransduced cells (Fig 2). In contrast, in Nef+
transduced cells, expression levels of both of these surface molecules
were up to 10 times lower in function of increasing EGFP expression
(Fig 2). Similar results were obtained with MOLT-4 and Jurkat T cell
lines (data not shown).
Nef Expression Hampers Human T-Cell Development The most immature thymocytes susceptible for HIV infection in vivo are immature CD4 single positive cells (CD4+CD3 CD8 ;
ISP4+),13,14 the precursors of DP immature
thymocytes and single positive (SP) mature thymocytes and T
cells. To study the effect of nef expression on human
T-cell development, ISP4+ cells were isolated by cell
sorting and transduced with Nef or Nef+
retroviral supernatant (Fig 3A). T-cell
development from transduced progenitor cells was assayed in vitro in
FTOC and in vivo after injection in the human thymus of SCID-hu mice.
After 1 week of FTOC, Nef transduced
ISP4+ cells developed into DP cells with comparable cell
membrane CD4, CD8 , and the TCR-associated CD3 expression levels as
nontransduced cells (Fig 3B), as EGFP expression does not hamper T-cell
development.24,25 In contrast, most Nef+
transduced thymocytes expressed reduced CD4, CD8 (Fig 3B), and MHC
class I levels (data not shown) and were skewed towards higher CD3
levels, all correlating with EGFP and thus with Nef levels. Gating on
EGFP+ cells (Fig 3C) showed that the Nef+
transduced cells were mainly
CD4dim/-CD8 +/dim, so that the DP fraction of
Nef+ transduced thymocytes was significantly reduced
(Table 1). Mean fluorescence intensities of
Nef versus Nef+ transduced thymocytes
(Fig 3C) were for CD4, 125 versus 26; for CD8 , 299 versus 165; for
CD3, 95 versus 124. Precursor expansion, ie, the ratio of output
transduced thymocyte number to input transduced progenitor number
(about 1,500 cells) was on the average 10.0 (range, 6.2 to 17) for
Nef transduced cells compared with 2.5 (range, 1.3 to 3.4), with Nef+ transduced cells (Table 1). In addition,
unlike the transduced ISP4+ start population, relatively
more Nef+ transduced thymocytes expressed intermediate EGFP
levels compared with Nef transduced cells, possibly
indicating a selective disadvantage for cells expressing high levels of
nef (Fig 3). The fraction of CD3+ cells expressing
CD4 was diminished (Fig 3C and Table 1). On Nef+ transduced
thymocytes, CD8 expression was less reduced than CD8 expression,
and similar to Nef , most Nef+ transduced
CD3+ cells expressed an ![]() TCR (data not shown). On
Nef+ thymocytes, ![]() TCR expression increased with EGFP
fluorescence intensity, similar to CD3. A minor subset of
Nef+ transduced thymocytes expressing normal CD4 and CD8
levels was present (Fig 3C). After additional weeks of culture, the
differences in thymocyte generation and phenotype in FTOC started with
Nef+ compared with Nef transduced
ISP4+ precursors were even more pronounced (Table 1). After
3 weeks of FTOC, almost no Nef+ DP cells were observed (Fig
3D and Table 1). The few remaining Nef+ cells were mostly
CD3+CD4dim/-CD8 + and either
CD8 + or CD8![]() . Thus, generation of
DP thymocytes from ISP4+ precursors decreases with
increasing nef expression.
T Cells Expressing nef Are Hyperproliferative Upon CD3 Triggering
Nef Expression Does Not Affect Generation or Function
of DCs
By retroviral gene transfer, we expressed the HIV molecular clone NL4-3
nef gene,26 the nef gene used in previous
studies on T-cell development in SCID-hu mice13,15-17 and
Tg mice,18,19,21,22 in T-cell and DC precursors. We have
shown here that expression of the nef gene induced
abnormalities of T-cell development. The number of thymocytes generated
from ISP4+ cells expressing nef was greatly
reduced. Immature thymocytes generated from nef expressing
precursor cells were CD4dim/-CD8 The authors thank N. Decabooter, C. De Boever, A. Moerman, V. Debacker,
M.-J. De Bosscher for technical assistance, A. De Creus, K. Van
Beneden, Dr J. Van Emmelo, Dr J. De Boever for expert technical advice,
Drs B. Vandekerckhove, G. Leclercq for critical reading of the
manuscript and continuous support, the Departments of Obstetrics,
Cardiac Surgery, and Pathology for the supply of human tissue, the
Department of Radiotherapy and Nuclear Medicine for irradiation
facilities, Dr H. Spits and collaborators (The Netherlands Cancer
Institute, Amsterdam, The Netherlands) for the gift of the IRES-EGFP
construct, Dr G.P. Nolan (Stanford University School of Medicine,
Stanford, CA) for the gift of the Phoenix-NA packaging cell line and
the LZRS vector. The following reagents were obtained through the AIDS
Research and Reference Reagent Program, Division of AIDS, NIAID, NIH:
pNL4-3 from Dr Malcolm Martin, HIV-1 Nef Monoclonal Antibody (EH-1) and
Sup-T1 cells from Dr J. Hoxie.
Submitted April 1, 1999; accepted June 15, 1999.
Supported by grants from the Gezamelijk Overlegde Actie (GOA)
University of Ghent, the Fund for Scientific Research-Flanders (Belgium), and the VIB. B.V. and T.K. are research assistants and D.V.
is a postdoctoral research fellow of the Fund for Scientific Research-Flanders (Belgium). E.N. is a VIB employee.
The publication costs of this
article were defrayed in part by
page charge payment. This article
must therefore be hereby marked
"advertisement"
in accordance with 18 U.S.C. section
1734 solely to indicate this fact.
Address reprint requests to Bruno Verhasselt, MD, Department of
Clinical Chemistry, Microbiology and Immunology, University of Ghent,
University Hospital of Ghent, 4 Blok A De Pintelaan 185, B-9000 Ghent,
Belgium; e-mail: Bruno.Verhasselt{at}rug.ac.be.
1.
Levy JA:
HIV and the Pathogenesis of AIDS (ed 2). Washington, DC, American Society of Microbiology, 1998
2.
Deacon NJ, Tsykin A, Solomon A, Smith K, Ludford-Menting M, Hooker DJ, McPhee DA, Greenway AL, Ellett A, Chatfield C, Lawson VA, Crowe S, Maerz A, Sonza S, Laermont J, Sullivan JS, Cunningham A, Dwyer D, Dowton D, Mills J:
Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients.
Science
270:988, 1995
3.
Kirchhoff F, Greenough TC, Brettler DB, Sullivan JL, Desrosiers RC:
Brief report: Absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection.
N Engl J Med
332:228, 1995
4.
Learmont JC, Geczy AF, Mills J, Ashton LJ, Raynes-Greenow CH, Garsia RJ, Dyer WB, McIntyre L, Oelrichs RB, Rhodes DI, Deacon NJ, Sullivan JS, for the Sydney Blood Bank Cohort Research Group:
Immunological and virological status after 14 to 18 years of infection with an attenuated strain of HIV-1.
N Engl J Med
340:1715, 1999
5.
Kestler HW III, Ringler DJ, Mori K, Panicali DL, Sehgal PK, Daniel MD, Desrosiers RC:
Importance of the nef gene for maintenance of high virus loads and for development of AIDS.
Cell
65:651, 1991[Medline]
[Order article via Infotrieve]
6.
Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK, Desrosiers RC:
Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene.
Science
258:1938, 1992
7.
Harris M:
From negative factor to a critical role in virus pathogenesis: The changing fortunes of Nef.
J Gen Virol
77:2379, 1996
8.
Peter F:
HIV nef: The mother of all evil?
Immunity
9:433, 1998[Medline]
[Order article via Infotrieve]
9.
Garcia JV, Miller AD:
Serine phosphorylation-independent downregulation of cell-surface CD4 by nef.
Nature
350:508, 1991[Medline]
[Order article via Infotrieve]
10.
Schwartz O, Marechal V, Le Gall S, Lemonnier F, Heard JM:
Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein.
Nat Med
2:338, 1996[Medline]
[Order article via Infotrieve]
11.
Douek DC, McFarland RD, Keiser PH, Gage EA, Massey JM, Haynes BF, Polis MA, Haase AT, Feinberg MB, Sullivan JL, Jamieson BD, Zack JA, Picker LJ, Koup RA:
Changes in thymic function with age and during the treatment of HIV infection.
Nature
396:690, 1998[Medline]
[Order article via Infotrieve]
12.
Gaulton GN, Scobie JV, Rosenzweig M:
HIV-1 and the thymus.
AIDS
11:403, 1997[Medline]
[Order article via Infotrieve]
13.
Jamieson BD, Zack JA:
In vivo pathogenesis of a human immunodeficiency virus type 1 reporter virus.
J Virol
72:6520, 1998
14.
Su L, Kaneshima H, Bonyhadi M, Salimi S, Kraft D, Rabin L, McCune JM:
HIV-1-induced thymocyte depletion is associated with indirect cytopathogenicity and infection of progenitor cells in vivo.
Immunity
2:25, 1995[Medline]
[Order article via Infotrieve]
15.
Jamieson BD, Aldrovandi GM, Planelles V, Jowett JB, Gao L, Bloch LM, Chen IS, Zack JA:
Requirement of human immunodeficiency virus type 1 nef for in vivo replication and pathogenicity.
J Virol
68:3478, 1994
16.
Aldrovandi GM, Zack JA:
Replication and pathogenicity of human immunodeficiency virus type 1 accessory gene mutants in SCID-hu mice.
J Virol
70:1505, 1996[Abstract]
17.
Aldrovandi GM, Gao LY, Bristol G, Zack JA:
Regions of human immunodeficiency virus type 1 nef required for function in vivo.
J Virol
72:7032, 1998
18.
Lindemann D, Wilhelm R, Renard P, Althage A, Zinkernagel R, Mous J:
Severe immunodeficiency associated with a human immunodeficiency virus 1 NEF/3'-long terminal repeat transgene.
J Exp Med
179:797, 1994
19.
Skowronski J, Parks D, Mariani R:
Altered T cell activation and development in transgenic mice expressing the HIV-1 nef gene.
EMBO J
12:703, 1993[Medline]
[Order article via Infotrieve]
20.
Brady HJ, Pennington DJ, Miles CG, Dzierzak EA:
CD4 cell surface downregulation in HIV-1 Nef transgenic mice is a consequence of intracellular sequestration.
EMBO J
12:4923, 1993[Medline]
[Order article via Infotrieve]
21.
Hanna Z, Kay DG, Cool M, Jothy S, Rebai N, Jolicoeur P:
Transgenic mice expressing human immunodeficiency virus type 1 in immune cells develop a severe AIDS-like disease.
J Virol
72:121, 1998
22.
Hanna Z, Kay DG, Rebai N, Guimond A, Jothy S, Jolicoeur P:
Nef harbors a major determinant of pathogenicity for an AIDS-like disease induced by HIV-1 in transgenic mice.
Cell
95:163, 1998[Medline]
[Order article via Infotrieve]
23.
Vanhecke D, Verhasselt B, Debacker V, Leclercq G, Plum J, Vandekerckhove B:
Differentiation to T helper cells in the thymus. Gradual acquisition of T helper cell function by CD3+CD4+ cells.
J Immunol
155:4711, 1995[Abstract]
24.
Verhasselt B, De Smedt M, Verhelst R, Naessens E, Plum J:
Retrovirally transduced CD34++ human cord blood cells generate T cells expressing high levels of the retroviral encoded green fluorescent protein marker in vitro.
Blood
91:431, 1998
25.
Heemskerk MH, Blom B, Nolan G, Stegmann AP, Bakker AQ, Weijer K, Res PC, Spits H:
Inhibition of T cell and promotion of natural killer cell development by the dominant negative helix loop helix factor Id3.
J Exp Med
186:1597, 1997
26.
Adachi A, Gendelman HE, Koenig S, Folks T, Willey R, Rabson A, Martin MA:
Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone.
J Virol
59:284, 1986
27.
Peault B, Weissman IL, Baum C, McCune JM, Tsukamoto A:
Lymphoid reconstitution of the human fetal thymus in SCID mice with CD34+ precursor cells.
J Exp Med
174:1283, 1991
28.
Rosenzwajg M, Camus S, Guigon M, Gluckman JC:
The influence of interleukin (IL)-4, IL-13, and Flt3 ligand on human dendritic cell differentiation from cord blood CD34+ progenitor cells.
Exp Hematol
26:63, 1998[Medline]
[Order article via Infotrieve]
29.
Smith SD, Shatsky M, Cohen PS, Warnke R, Link MP, Glader BE:
Monoclonal antibody and enzymatic profiles of human malignant T-lymphoid cells and derived cell lines.
Cancer Res
44:5657, 1984
30.
Champseix C, Marechal V, Khazaal I, Schwartz O, Fournier S, Schlegel N, Dranoff G, Danos O, Blot P, Vilmer E, Heard JM, Peault B, Lehn P:
A cell surface marker gene transferred with a retroviral vector into CD34+ cord blood cells is expressed by their T-cell progeny in the SCID-hu thymus.
Blood
88:107, 1996
31.
Vanhecke D, Leclercq G, Plum J, Vandekerckhove B:
Characterization of distinct stages during the differentiation of human CD69+CD3+ thymocytes and identification of thymic emigrants.
J Immunol
155:1862, 1995[Abstract]
32.
Shearer GM:
HIV-induced immunopathogenesis.
Immunity
9:587, 1998[Medline]
[Order article via Infotrieve]
33.
Granelli Piperno A, Delgado E, Finkel V, Paxton W, Steinman RM:
Immature dendritic cells selectively replicate macrophagetropic (M-tropic) human immunodeficiency virus type 1, while mature cells efficiently transmit both M- and T-tropic virus to T cells.
J Virol
72:2733, 1998
34.
Meyaard L, Schuitemaker H, Miedema F:
T-cell dysfunction in HIV infection: anergy due to defective antigen-presenting cell function?
Immunol Today
14:161, 1993[Medline]
[Order article via Infotrieve]
35.
Hellerstein M, Hanley MB, Cesar D, Siler S, Papageorgopoulos C, Wieder E, Schmidt D, Hoh R, Neese R, Macallan D, Deeks S, McCune JM:
Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans.
Nat Med
5:83, 1999[Medline]
[Order article via Infotrieve]
36.
von Boehmer H:
Aspects of lymphocyte developmental biology.
Immunol Today
18:260, 1997[Medline]
[Order article via Infotrieve]
37.
Jamieson BD, Uittenbogaart CH, Schmid I, Zack JA:
High viral burden and rapid CD4+ cell depletion in human immunodeficiency virus type 1-infected SCID-hu mice suggest direct viral killing of thymocytes in vivo.
J Virol
71:8245, 1997[Abstract]
38.
Rahemtulla A, Fung Leung WP, Schilham MW, Kundig TM, Sambhara SR, Narendran A, Arabian A, Wakeham A, Paige CJ, Zinkernagel RM, Miller RG, Mak TW:
Normal development and function of CD8+ cells but markedly decreased helper cell activity in mice lacking CD4.
Nature
353:180, 1991[Medline]
[Order article via Infotrieve]
39.
Itano A, Cado D, Chan FK, Robey E:
A role for the cytoplasmic tail of the beta chain of CD8 in thymic selection.
Immunity
1:287, 1994[Medline]
[Order article via Infotrieve]
40.
Garcia JV, Alfano J, Miller AD:
The negative effect of human immunodeficiency virus type 1 Nef on cell surface CD4 expression is not species specific and requires the cytoplasmic domain of CD4.
J Virol
67:1511, 1993
41.
Aiken C, Konner J, Landau NR, Lenburg ME, Trono D:
Nef induces CD4 endocytosis: Requirement for a critical dileucine motif in the membrane-proximal CD4 cytoplasmic domain.
Cell
76:853, 1994[Medline]
[Order article via Infotrieve]
42.
Norment AM, Littman DR:
A second subunit of CD8 is expressed in human T cells.
EMBO J
7:3433, 1988[Medline]
[Order article via Infotrieve]
43.
Le Gall S, Erdtmann L, Benichou S, Berlioz Torrent C, Liu L, Benarous R, Heard JM, Schwartz O:
Nef interacts with the µ subunit of clathrin adaptor complexes and reveals a cryptic sorting signal in MHC I molecules.
Immunity
8:483, 1998[Medline]
[Order article via Infotrieve]
44.
Spina CA, Kwoh TJ, Chowers MY, Guatelli JC, Richman DD:
The importance of nef in the induction of human immunodeficiency virus type 1 replication from primary quiescent CD4 lymphocytes.
J Exp Med
179:115, 1994
45.
Miller MD, Warmerdam MT, Gaston I, Greene WC, Feinberg MB:
The human immunodeficiency virus-1 nef gene product: A positive factor for viral infection and replication in primary lymphocytes and macrophages.
J Exp Med
179:101, 1994
46.
Du Z, Lang SM, Sasseville VG, Lackner AA, Ilyinskii PO, Daniel MD, Jung JU, Desrosiers RC:
Identification of a nef allele that causes lymphocyte activation and acute disease in macaque monkeys.
Cell
82:665, 1995[Medline]
[Order article via Infotrieve]
47.
Anderson G, Moore NC, Owen JJ, Jenkinson EJ:
Cellular interactions in thymocyte development.
Annu Rev Immunol
14:73, 1996[Medline]
[Order article via Infotrieve]
48.
Xu X-N, Laffert B, Screaton GR, Kraft M, Wolf D, Kolanus W, Mongkolsapay J, McMichael AJ, Baur AS:
Induction of Fas ligand expression by HIV involves the interaction of Nef with the T cell receptor
49.
Cella M, Engering A, Pinet V, Pieters J, Lanzavecchia A:
Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells.
Nature
388:782, 1997[Medline]
[Order article via Infotrieve]
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 1999 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||